Identification
NameTyloxapol
Accession NumberDB06439
TypeSmall Molecule
GroupsApproved, Investigational
Description

Tyloxapol is a non-ionic detergent often used as a surfactant.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlevaireNot Available
Brand mixturesNot Available
Categories
UNIIY27PUL9H56
CAS number25301-02-4
WeightAverage:
Monoisotopic:
Chemical FormulaNot Available
InChI KeyUTFVNNPSMPINLE-UHFFFAOYSA-N
InChI
InChI=1S/C51H80O6/c1-35-25-41(50(13,14)33-47(5,6)7)29-37(44(35)56-23-20-53)27-39-31-42(51(15,16)34-48(8,9)10)30-38(45(39)57-24-21-54)26-36-28-40(17-18-43(36)55-22-19-52)49(11,12)32-46(2,3)4/h17-18,25,28-31,52-54H,19-24,26-27,32-34H2,1-16H3
IUPAC Name
SMILES
Pharmacology
Indication

Used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions, administered by inhalation through a nebulizer or with a stream of oxygen. Also investigated for use/treatment in cystic fibrosis and pediatric indications.

Structured Indications Not Available
Pharmacodynamics

It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions. Tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins.

Mechanism of action

Tyloxapol, when injected IP, blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. It has also been shown to be inhibitor of lipoprotein lipase, thus preventing triglyceride uptake.

TargetKindPharmacological actionActionsOrganismUniProt ID
Lipoprotein lipaseProteinyes
inhibitor
HumanP06858 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
Toxicity

Acute oral LD50 in 1000 mg/kg in mouse and 5000 mg/kg in rat.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bhatia AJ, Wade GN: Effects of pregnancy and ovarian steroids on fatty acid synthesis and uptake in Syrian hamsters. Am J Physiol. 1991 Jan;260(1 Pt 2):R153-8. [PubMed:1992816 ]
External Links
ATC CodesR05CA01 — Tyloxapol
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.4 KB)
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Enuclene drops0.69USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as linear diarylheptanoids. These are diarylheptanoids with an open heptane chain. The two aromatic rings are linked only by the heptane chain.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassDiarylheptanoids
Sub ClassLinear diarylheptanoids
Direct ParentLinear diarylheptanoids
Alternative ParentsDiphenylmethanes / Phenylpropanes / Phenoxy compounds / Phenol ethers / Toluenes / Alkyl aryl ethers / Primary alcohols / Hydrocarbon derivatives
SubstituentsLinear 1,7-diphenylheptane skeleton / Diphenylmethane / Phenylpropane / Phenoxy compound / Phenol ether / Alkyl aryl ether / Toluene / Monocyclic benzene moiety / Benzenoid / Ether
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Triglyceride lipase activity
Specific Function:
The primary function of this lipase is the hydrolysis of triglycerides of circulating chylomicrons and very low density lipoproteins (VLDL). Binding to heparin sulfate proteogylcans at the cell surface is vital to the function. The apolipoprotein, APOC2, acts as a coactivator of LPL activity in the presence of lipids on the luminal surface of vascular endothelium (By similarity).
Gene Name:
LPL
Uniprot ID:
P06858
Molecular Weight:
53162.07 Da
References
  1. Levine S, Saltzman A: A procedure for inducing sustained hyperlipemia in rats by administration of a surfactant. J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):224-6. Epub 2006 Jun 3. [PubMed:16839786 ]
  2. Rodrigues B, Braun JE, Spooner M, Severson DL: Regulation of lipoprotein lipase activity in cardiac myocytes from control and diabetic rat hearts by plasma lipids. Can J Physiol Pharmacol. 1992 Sep;70(9):1271-9. [PubMed:1493594 ]
  3. Sato K, Akiba Y, Horiguchi M: Species differences between chickens and rats in chemical properties of adipose tissue lipoprotein lipase. Comp Biochem Physiol A Physiol. 1997 Nov;118(3):855-8. [PubMed:9406449 ]
Drug created on March 19, 2008 10:33 / Updated on June 11, 2017 21:01